These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11081447)

  • 41. [Value of determining serum cholesterol levels in patients with coronary heart disease].
    Stalenhoef AF
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2545-8. PubMed ID: 9555153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medical management of coronary artery disease revisited: the endothelial factor.
    Siegel JA
    J S C Med Assoc; 1997 Sep; 93(9):333-5. PubMed ID: 9316336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statins in acute coronary syndromes.
    Sposito AR; Aguiar Filho GB; Aarão AR; Sousa FT; Bertolami MC
    Arq Bras Cardiol; 2011 Oct; 97(4):350-6. PubMed ID: 22124628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluvastatin: effects beyond cholesterol lowering.
    Corsini A
    J Cardiovasc Pharmacol Ther; 2000 Jul; 5(3):161-75. PubMed ID: 11150405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of lipid lowering in coronary artery disease.
    Goldberg AC
    Curr Opin Cardiol; 1997 Sep; 12(5):488-93. PubMed ID: 9352177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies.
    Archbold RA; Timmis AD
    Curr Opin Lipidol; 1999 Dec; 10(6):527-34. PubMed ID: 10680047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
    De Caterina R; Lenzi S
    G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Auer J; Weber T; Eber B
    N Engl J Med; 2004 Aug; 351(7):714-7; author reply 714-7. PubMed ID: 15309747
    [No Abstract]   [Full Text] [Related]  

  • 50. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
    Kanadaşi M; Cayli M; Demirtaş M; Inal T; Demir M; Koç M; Avkaroğullari M; Dönmez Y; Usal A; Alhan CC; San M
    Heart Vessels; 2006 Sep; 21(5):291-7. PubMed ID: 17151816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statin withdrawal: clinical implications and molecular mechanisms.
    Cubeddu LX; Seamon MJ
    Pharmacotherapy; 2006 Sep; 26(9):1288-96. PubMed ID: 16945051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
    Alemao E; Yin D; Sintonen H; Salomaa V; Jousilahti P
    Am J Cardiovasc Drugs; 2006; 6(5):349-55. PubMed ID: 17083270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What do the statins tell us?
    LaRosa JC
    Am Heart J; 2002 Dec; 144(6 Suppl):S21-6. PubMed ID: 12486412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of intensive statin therapy in the elderly.
    Maroo BP; Lavie CJ; Milani RV
    Am J Geriatr Cardiol; 2008; 17(2):92-100. PubMed ID: 18326948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current questions regarding the use of statins in patients with coronary heart disease.
    Rallidis LS; Lekakis J; Kremastinos DT
    Int J Cardiol; 2007 Nov; 122(3):188-94. PubMed ID: 17399827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid-lowering therapies in the management of acute coronary syndromes.
    Mosca L; Biviano A;
    Curr Cardiol Rep; 2002 Jul; 4(4):320-6. PubMed ID: 12052271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cholesterol reduction and its impact on coronary artery disease and total mortality.
    Holme I
    Am J Cardiol; 1995 Sep; 76(9):10C-17C. PubMed ID: 7572677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of statins in acute coronary syndromes.
    Foody JM; Nissen SE
    Am J Cardiol; 2001 Aug; 88(4A):31F-5F. PubMed ID: 11520485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.